Gastro Retentive Multiparticulate Drug Delivery System for Cefuroxime Axetil
Gastro retentive multiparticulate drug delivery system for Cefuroxime Axetil
Keywords:
Floating Microsphere, Ethyl Cellulose, Hydroxypropyl Methyl Cellulose (HPMC), Eudragit L, 100 and ChitosanAbstract
The main aim of present study was to build up multiparticulate gastro retentive drug delivery system of Cefuroxime which is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. The gastro retentive drug delivery system can be formulated to enhance the bio-availability of Cefuroxime Axetilby retaining the system into the stomach for extended period of time. Cefuroxime Axetil is a poorly water-soluble drug (BCS Class-II drug) and its bioavailability is exceedingly low. The rate of absorption and the extent of bioavailability for such insoluble drug are restricted by the rate of dissolution in the gastrointestinal fluids. The gastroretentive drug delivery system of Cefuroxime Axetil wasprimed by emulsion solvent diffusion method by using ethyl cellulose, Eudragit L100, HPMC, Chitosanpolymers in changeable concentration. All formulations were evaluated for percent yield, particle size, entrapment efficiency, in vitro buoyancy as well as in vitro release studies. The resultant formulations showed superior buoyancy and invitro controlled release of Cefuroxime Axetil.
How to cite this article: Varma AK, Kushwaha S. Gastro Retentive Multiparticulate Drug Delivery System for Cefuroxime Axetil. J Durg Dis Dev 2019; 3(1): 10-14.
References
Norman GB. Herbal drugs and phytopharmaceuticals. A Handbook for Practice on a Scientific Basis. New York: Medpharm Scientific Publishers, Stuttgart and CRC Press. 2001; 2: 230-48.
Chien YW. Novel drug delivery system, Marcel Dekker Inc Publications: New York, 1992; 2(50): 16172.
Khar RK, Vyas SP. Targeted and controlled drug delivery novel carrier system, CBS Publishers and Distributors: New Delhi, 2002; 1: 417-454.
Arora S, Ali J, Ahuja A et al. Floatng drug delivery systems: A review. AAPS Pharm Sci Tech 2005; 6(3): 372-390.
Wahlstrom B, BlennowG. A study on the fate of curcumin in the rat, ActaPharmacolToxicol, 1978; 43:86-92.
AnandP, Kunnumakkara AB, Newman RA. Bioavailability of Curcumin: Problems and Promises, Mol Pharmaceutics, 2007; 4(6): 807-818.
Smart JD, Khllaway IW. Pharmaceutical factors influencing the rate of gastrointestinal transit in an animal model. Int J Pharm 1989; 53: 79-83.
Sheth PR, Tossounian J. The Hydrodynamically Balanced System (HBS): A Novel Drug Delivery System for Oral Use. Drug Dev. Ind. Pharm. 1984; 10: 313-339.
Ranajit KB, Ishita C, kaushik B, Uday B. Turmeric and curcumin: Biological actions and medicinal applications. Current science 2004; 87: 44-53.
Ireson CR, Jones DJ, Orr S et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidem. Biomar Prev 2002; 11: 105-111.
Kawashima Y, Niwa T, Takeuchi H et al. Hollow microspheres for use as a floating controlled drug delivery system in the stomach. Pharm Sci 1992; 81: 135-140.
Parasuram RR, Moidutty L, Chetan H. Preparation and evaluation of delayed release aceclofenac microspheres. Asian J Pharm 2008; 2(4): 52-54.
Pusp RN, Myung KC, Hoo KC. Preparation of floating microspheres for fish farming. Int J Pharm 2007; 341: 85-90.
Patel AR, Mahajan AN, Shah DA. Preparation and in vitro characterization of porous carrier-based floating microspheres of model drug for gastric delivery, Der Pharmacia Lettre. 2011; 3(3): 432-442.
Maheswari U, Jain S, Bhadra D et al. Floating microspheres bearing acetohydroxamic acid for the treatment of H. pylori. J Pharm Pharmacol 2003; 55: 1607-1613.
Rahman MH, TelnyT, Kumaraswamy K. Comparative evaluation of HPMC K100 and poloxamer 188- influence on release kinetics of Curcumin in floating microspheres. R J Pharm Chem Biol Sci 2010; 1(2): 28-34.
Downloads
Published
How to Cite
Issue
Section
License
We, the undersigned, give an undertaking to the following effect with regard to our article entitled
“_______________________________________________________________________________________________________________________________________________________________________________
________________________________________________________________________________” submitted for publication in (Journal title)________________________________________________ _______________________________________________________Vol.________, Year _________:-
1. The article mentioned above has not been published or submitted to or accepted for publication in any form, in any other journal.
2. We also vouchsafe that the authorship of this article will not be contested by anyone whose name(s) is/are not listed by us here.
3. I/We declare that I/We contributed significantly towards the research study i.e., (a) conception, design and/or analysis and interpretation of data and to (b) drafting the article or revising it critically for important intellectual content and on (c) final approval of the version to be published.
4. I/We hereby acknowledge ADRs conflict of interest policy requirement to scrupulously avoid direct and indirect conflicts of interest and, accordingly, hereby agree to promptly inform the editor or editor's designee of any business, commercial, or other proprietary support, relationships, or interests that I/We may have which relate directly or indirectly to the subject of the work.
5. I/We also agree to the authorship of the article in the following sequence:-
Authors' Names (in sequence) Signature of Authors
1. _____________________________________ _____________________________________
2. _____________________________________ _____________________________________
3. _____________________________________ _____________________________________
4. _____________________________________ _____________________________________
5. _____________________________________ _____________________________________
6. _____________________________________ _____________________________________
7. _____________________________________ _____________________________________
8. _____________________________________ _____________________________________
Important
(I). All the authors are required to sign independently in this form in the sequence given above. In case an author has left the institution/ country and whose whereabouts are not known, the senior author may sign on his/ her behalf taking the responsibility.
(ii). No addition/ deletion/ or any change in the sequence of the authorship will be permissible at a later stage, without valid reasons and permission of the Editor.
(iii). If the authorship is contested at any stage, the article will be either returned or will not be
processed for publication till the issue is solved.
